Two U.S. hospitals implant first Biotronik pacemakers with Home Monitoring Technology

Lake Oswego 23 October 2001The California-based Stanford University Medical Center and Providence Everett Medical Center in Seattle, Washington, became the first two medical facilities in the United States to implant Biotronik's novel pacemaker which features Home Monitoring Technology. Home Monitoring is the first technology of its kind to be approved by the Food and Drug Administration, and is anticipated to revolutionise the way physicians currently monitor their pacemaker patients.


Sung H. Chun M.D., Assistant Professor of Medicine, Associate Director of Cardiac Electrophysiology and Arrhythmia Service, and Director of Pacemaker Service at Stanford University Medical Center, and Jeffery S. Rose M.D., FACC Cardiologist Electrophysiologist at Providence Everett Medical Center performed the procedures.

Dr. Chun stated: "The Home Monitoring system we implanted is one of the most exciting technologies that have been developed in the field of arrhythmia management. This technology will serve as a platform to deliver true 21st century patient care by allowing physicians to provide more prompt response as well as more complete patient management to those with arrhythmia problems. Using this technology, we will soon be able to monitor, diagnose, trouble-shoot, and perhaps even initiate treatment for various arrhythmia and device issues while patients are sitting at home."

The two patients, who received the Home Monitoring pacemaker systems, mark the beginning of a nationwide study led by Dr. Sung Chun at Stanford University Medical Center. Traditionally, pacemaker patients typically see their physician on an annual or bi-annual basis. With Home Monitoring, the pacemaker can be customised to automatically transmit a detailed Cardio Report to the physician's office on a daily or weekly basis and if the patient experiences a significant change in their heart condition. This continuous monitoring is anticipated to allow the patient's clinician to be able to respond quickly and more efficiently to their patient's constantly changing cardiac status.

Dr. Antonio Chan, who is a co-investigator and professor at Stanford, and also assisted in the implant in California, commented: "A quantum leap in cardiac arrhythmia therapy and pacemaker surveillance has occurred. This is America's first ever implant of such a breakthrough device." Dr. Chan is a leading cardiologist with international patients from Asia and Europe. He envisions that this remote wireless pacemaker is a critical telemedicine application, where cardiologists could eventually monitor their patients with cardiovascular conditions anywhere in the world.

The main objective of the upcoming study will be to further assess the clinical applications of Home Monitoring and the Medical Communication Service. Biotronik is the first company to commercially utilise the Medical Implant Communication Service for remote monitoring of pacemakers. Thomas Brown, Biotronik's Executive Vice President, stated: "The Home Monitoring feature incorporated in select Biotronik pacemakers and soon to be incorporated in select implantable cardiac defibrillators (ICDs) is a significant step towards automating remote patient management related to cardiac pacemakers and implantable cardiac defibrillators. This is the first step in an evolutionary process that will allow Biotronik to provide significant value added services to our customers both today and in the future."

Biotronik Inc. is recognised worldwide as a complete provider of cardiovascular products of the highest quality and reliability. The company is committed to researching and developing new biomedical products. Its unmatched reliability record is the result of maintaining the highest standards in engineering and design. The company's U.S. headquarters is located in Lake Oswego, Oregon, and its worldwide headquarters is in Berlin, Germany.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]